Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Cellectis S.A.. (11/13/17). "Press Release: Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017". New York, NY.

Organisations Organisation Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
  Organisation 2 Calyxt Inc. (Nasdaq Global Market: CLXT)
  Group Cellectis (Group)
Products Product UCART123 (Cellectis)
  Product 2 UCART19 (Cellectis / Servier / Pfizer / Allogene)
Index term Index term Cellectis–SEVERAL: investment, 201706–201707 Calyxt IPO $64.4m w 7m+1.05m common shares at $8/share Cellectis retains 79.9% shareholding
Persons Person Simon, Mathieu (Cellectis 2013–201803 COO joined 201204 as SVP Cellectis Group before Pierre Fabre + Wyeth RETIRED 3/18)
  Person 2 Harnest, Simon (Cellectis 201505 VP Finance + Investor Relations before Trout Group)

Record changed: 2017-11-26


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Cellectis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top